Nebius Falls 40% From Record as H2 Revenue Bar Rises and Backlog Looks Large

What happened

Nebius shares have dropped roughly 40% from their record high, reflecting a market reassessment of execution risk against a still-demand-heavy growth story. The company now needs second-half 2026 revenue to more than double its first-half level to hit its full-year outlook, a bar that depends on smooth activation of late-2026 capacity. Its signed backlog of unrecognized contract revenue reached approximately $37.5 billion by the end of Q2, but that backlog only translates into reported revenue as delivered capacity and services come online under strict customer terms. The market continues to treat Nebius as a scarce AI-infrastructure asset with pricing power, yet the valuation at about 118x EV/EBITDA and a $56.97 billion market cap already assumes strong conversion of that backlog. The latest commentary keeps the near-term focus on whether post-October pricing holds and whether financing shifts away from large convertibles toward prepayments, secured debt, and partner capital.

Implication

The 40% drawdown does not automatically make NBIS cheap: the stock still prices in sustained scarcity, successful October price increases, and smooth conversion of late-2026 capacity into 2027 revenue. The backlog number of $37.5 billion is contractual but not yet revenue, and it can be undermined by service credits, tranche delays, or termination clauses under Microsoft and Meta. The key near-term checks are whether Q3/Q4 disclosures show realized ACV per MW above Q2 levels after the price reset, and whether funding moves away from more convertible dilution. If those checks fail, the fair value range shifts toward the bear scenario near $170; if they pass, the bull scenario near $320 becomes more plausible. Until then, disciplined investors should treat any bounce as an opportunity to reassess rather than chase.

Thesis delta

The investment thesis does not change, but the evidence bar has risen. The stock's 40% decline confirms that paying for backlog growth without execution proof was too aggressive, and the need for H2 revenue to more than double H1 converts a long-term demand story into a near-term delivery test. No rating change: remain WAIT, with re-assessment tied to H2 revenue trajectory and funding mix.